Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseLars Wallentin, Agneta Siegbahn, Joseph A. Jakubowski et al.|European Heart Journal|2007Cited by 457
Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex VivoDavid Erlinge, Lars Wallentin, Christoph Varenhorst et al.|Journal of the American College of Cardiology|2008Cited by 216
Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirinChristoph Varenhorst, Agneta Siegbahn, Stefan James et al.|American Heart Journal|2009Cited by 94
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathwaysDominick J Angiolillo, Oscar Ö. Braun, José Luis Ferreiro et al.|Thrombosis and Haemostasis|2013Cited by 18
Caffeine and incidence of dyspnea in patients treated with ticagrelorDaniel Lindholm, Christoph Varenhorst, Stefan James et al.|American Heart Journal|2018Cited by 5